Lebrikizumab Tied to Sustained Atopic Dermatitis Treatment Effect
Findings seen despite negligible remaining lebrikizumab serum concentrations following treatment withdrawal
Pandemic-Era Tax Credits Made Healthcare More Affordable, But They’re Set to Expire
No Evidence That Live Vaccines Are Unsafe for Patients on Dupilumab
Systematic review shows vaccine efficacy not affected by dupilumab in general
Health Care Spending Growth Projected to Outpace GDP to 2032
National health expenditures projected to have increased 7.5 percent in 2023, when COVID-19 public health emergency ended
Adverse Effects of Medical Treatment Increasing Worldwide
In high sociodemographic index region, age effects showed higher incidence rate in older adults
ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma
Neoadjuvant treatment followed by surgery results in longer event-free survival for resectable, macroscopic stage III melanoma
9.6 Percent of Medical Visits Took Place Via Telehealth in 2021
Percentage of telehealth visits was higher for mental health than other clinicians
1.5 Percent Ruxolitinib Cream Safe, Effective for Teens With Eczema
Ruxolitinib cream well tolerated, and disease control maintained over a year with as-needed use
Bimekizumab Yields Meaningful Response in Hidradenitis Suppurativa
Rapid clinically meaningful response seen, which was maintained for 48 weeks for moderate-to-severe hidradenitis suppurativa
2007 to 2019 Saw Increase in Inflation-Adjusted Health Care Spending
From 2007 to 2019, medical burden increased from 23.5 to 26.4 percent for low-income families and from 5.4 to 6.5 percent for higher-income families
